Fatih Tanriverdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatih Tanriverdi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Fahrettin Kelestimur
8 shared publications- Kursad Unluhizarci
Department of Endocrinology, Erciyes University Medical School, Kayseri, Türkiye
8 shared publications - Zuleyha Karaca
Department of Endocrinology, Faculty of Medicine, Erciyes University, 38030 Kayseri, Türkiye
8 shared publications - Sevda Ismailogullari
Department of Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkiye
2 shared publications Asli Sezgin Caglar
1 shared publicationAtilla Coruh
1 shared publication
Latest Publications
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
The comparison of combination test either with 1 μg acth test and glucagon test for the evaluation of hypothalamo-pituitary-adrenal axis in patients with pituitary disorders
The low-dose (1 μg) ACTH stimulation test or glucagon stimulation test (GST) are candidate tests for hypothalamo-pituitary-adrenal (HPA) axis evaluation in patients with pituitary disorders. In this study, we aimed to compare the combination of low-dose ACTH and GSTs (named as combination test) with each test results alone in the evaluation of HPA axis in patients with pituitary disorders whether combination test may overcome the problems when the test results are equivocal. Patients and methods: Forty-one adult patients with pituitary disorders and 20 healthy subjects were included in the study. Patients with diabetes mellitus or with the diagnosis of Cushing’s syndrome were not included in the study. Low-dose ACTH test, GST and combination tests were performed on separate days. Blood samples for the measurement of cortisol were obtained in the basal state and at 30, 60, 90 and 120 min after the administration of 1 μg ACTH intravenously. The lowest peak cortisol value of control subjects (14.6 μg/dl) was considered as the cut-off value for adrenal insufficiency in low-dose ACTH test. The GST was performed by subcutaneous injection of 1 mg glucagon. Blood samples for measurement of cortisol were obtained at 90, 120, 150, 180, 210 and 240 min after glucagon injection. The lowest peak cortisol value of control cubjects (9.7 μg/dl) was considered as the cut-off value for adrenal insufficiency. Combination test was performed by injecting 1 μg of ACTH at the 180 min of GST and blood samples for cortisol measurement were obtained at 210 and 240 minutes. For the determination of optimal cut-off value for diagnosing adrenal insufficiency, Receiver Operating Characteristics (ROC) analysis was performed and 12.4 μg/dl of cortisol value was obtained with a sensitivity of 83% and specificity of 100%. Results: Ten patients with adrenal insufficiency in both tests also had adrenal insufficiency in the combination test. Twenty-eight patients with normal cortisol response to both tests also had normal cortisol response to combination test. Two patients with adrenal insufficiency (peak cortisol responses were 13.4 and 13.1 μg/dl) at ACTH test and a patient with adrenal insufficiency at GST (peak cortisol response 8.7 μg/dl) had normal cortisol responses to combination test. Conclusion: The combination test gave an additional information in three (7.3%) patients who had equivocal results in ACTH and glucagon tests. Moreover, by performing the combination test, we can save a day of the patients and evaluate GH axis concomitantly.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
The comparison of combination test either with 1 μg acth test and glucagon test for the evaluation of hypothalamo-pituitary-adrenal axis in patients with pituitary disorders
The low-dose (1 μg) ACTH stimulation test or glucagon stimulation test (GST) are candidate tests for hypothalamo-pituitary-adrenal (HPA) axis evaluation in patients with pituitary disorders. In this study, we aimed to compare the combination of low-dose ACTH and GSTs (named as combination test) with each test results alone in the evaluation of HPA axis in patients with pituitary disorders whether combination test may overcome the problems when the test results are equivocal. Patients and methods: Forty-one adult patients with pituitary disorders and 20 healthy subjects were included in the study. Patients with diabetes mellitus or with the diagnosis of Cushing’s syndrome were not included in the study. Low-dose ACTH test, GST and combination tests were performed on separate days. Blood samples for the measurement of cortisol were obtained in the basal state and at 30, 60, 90 and 120 min after the administration of 1 μg ACTH intravenously. The lowest peak cortisol value of control subjects (14.6 μg/dl) was considered as the cut-off value for adrenal insufficiency in low-dose ACTH test. The GST was performed by subcutaneous injection of 1 mg glucagon. Blood samples for measurement of cortisol were obtained at 90, 120, 150, 180, 210 and 240 min after glucagon injection. The lowest peak cortisol value of control cubjects (9.7 μg/dl) was considered as the cut-off value for adrenal insufficiency. Combination test was performed by injecting 1 μg of ACTH at the 180 min of GST and blood samples for cortisol measurement were obtained at 210 and 240 minutes. For the determination of optimal cut-off value for diagnosing adrenal insufficiency, Receiver Operating Characteristics (ROC) analysis was performed and 12.4 μg/dl of cortisol value was obtained with a sensitivity of 83% and specificity of 100%. Results: Ten patients with adrenal insufficiency in both tests also had adrenal insufficiency in the combination test. Twenty-eight patients with normal cortisol response to both tests also had normal cortisol response to combination test. Two patients with adrenal insufficiency (peak cortisol responses were 13.4 and 13.1 μg/dl) at ACTH test and a patient with adrenal insufficiency at GST (peak cortisol response 8.7 μg/dl) had normal cortisol responses to combination test. Conclusion: The combination test gave an additional information in three (7.3%) patients who had equivocal results in ACTH and glucagon tests. Moreover, by performing the combination test, we can save a day of the patients and evaluate GH axis concomitantly.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Investigation of the pituitary functions long-term after the acute CNS infections
Objectives: Acute bacterial or viral CNS infections have been shown to result in hypopituitarism during the acute phase, and 6–24 months after the event in a few studies. However, there are no data in the literature regarding the long term pituitary functions after acute CNS infections. This cross-sectional study was designed to evaluate the pituitary functions long-term after the acute bacterial or viral CNS infections. Methods: 19 patients with ages 18–65 (mean: 39.53±17.089 years; 11 male patients, eight patients female) were included in the study. There were seven patients with acute bacterial meningitis, nine patients with acute viral encephalitis, and three cases of acute meningoencephalitis. Basal pituitary hormone levels were measured and glucagon stimulation test was performed 17–92 months (mean 48.47±25.19 months) after the acute CNS infections. MRI was performed to evaluate the pituitary gland volume and to rule out any co-incidental pituitary mass. Results: There were a total of 5 patients out of 19 (26.3%) with hypopituitarism; 3 (15.7%) with isolated GH deficiency, 1 (5.2%) with isolated FSH-LH deficiency and 1 (5.2%) with combined FSH-LH and GH deficiency in the study group. Mean pituitary volume was substantially lower in patients with hypopituitarism when compared to the patients without hypopituitarism. But the difference was not statistically significant. Conclusion: This study clearly demonstrated that high frequency hypopituitarism, GH deficiency in particular, was still present long term after the acute bacterial or viral CNS infections. Therefore, the patients with acute meningitis, meningoencephalitis and/or encephalitis need to be screened at least 4–5 years after the acute event.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Investigation of the pituitary functions long-term after the acute CNS infections
Objectives: Acute bacterial or viral CNS infections have been shown to result in hypopituitarism during the acute phase, and 6–24 months after the event in a few studies. However, there are no data in the literature regarding the long term pituitary functions after acute CNS infections. This cross-sectional study was designed to evaluate the pituitary functions long-term after the acute bacterial or viral CNS infections. Methods: 19 patients with ages 18–65 (mean: 39.53±17.089 years; 11 male patients, eight patients female) were included in the study. There were seven patients with acute bacterial meningitis, nine patients with acute viral encephalitis, and three cases of acute meningoencephalitis. Basal pituitary hormone levels were measured and glucagon stimulation test was performed 17–92 months (mean 48.47±25.19 months) after the acute CNS infections. MRI was performed to evaluate the pituitary gland volume and to rule out any co-incidental pituitary mass. Results: There were a total of 5 patients out of 19 (26.3%) with hypopituitarism; 3 (15.7%) with isolated GH deficiency, 1 (5.2%) with isolated FSH-LH deficiency and 1 (5.2%) with combined FSH-LH and GH deficiency in the study group. Mean pituitary volume was substantially lower in patients with hypopituitarism when compared to the patients without hypopituitarism. But the difference was not statistically significant. Conclusion: This study clearly demonstrated that high frequency hypopituitarism, GH deficiency in particular, was still present long term after the acute bacterial or viral CNS infections. Therefore, the patients with acute meningitis, meningoencephalitis and/or encephalitis need to be screened at least 4–5 years after the acute event.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Decreased skin capacitance and elasticity may be reversible after treatment of Cushing's syndrome
Background: Acne, stria and decreased skin elasticity are dermatological features of Cushing’s syndrome (CS). Although it is known that collagen mass in skin is decreased in CS and glucocorticoids play a role in acneiform skin lesions, the dermatological findings of CS has not previously been measured by reliable methods. Objective: The aim of the present study was to measure skin elasticity, capacitance, sebum content, pH and temperature in CS before and after 12 months of treatment. Methods: Twenty patients with CS and 11 healthy control subjects were included in the study. Skin properties were measured on dorsum of both hands by Cutameter, Corneometer CM825, Sebumeter SM810, Phmeter PH900 as non-invasive reliable measuring methods. Patients were treated for CS with surgery and they were reevaluated 12 months after. Results: The sebum content, temperature and capacitance of the skin were found to be significantly decreased in patients with CS compared to healthy controls on dorsum of both hands at baseline. The skin capacitance in CS was found to be similar to healthy controls after treatment, however the increment was not found to be significant compared to baseline. The sebum and temperature of the skin did not show significant changes according to baseline and was still significantly lower than healthy controls. Although statistically not significant, the elasticity of the skin was lower in CS than in the controls. The elasticity of the skin was found to be significantly increased a year after treatment. There was no correlation of skin elasticity, capacitance, temperature and sebum content of the skin with morning or midnight cortisol, urinary free cortisol or ACTH levels at baseline. Conclusion: This study revealed a hypothermic skin surface with decreased sebum secretion and capacitance and mildly decreased skin elasticity in CS. The decreased elasticity and capacitance of the skin may increase after treatment of CS.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Decreased skin capacitance and elasticity may be reversible after treatment of Cushing's syndrome
Background: Acne, stria and decreased skin elasticity are dermatological features of Cushing’s syndrome (CS). Although it is known that collagen mass in skin is decreased in CS and glucocorticoids play a role in acneiform skin lesions, the dermatological findings of CS has not previously been measured by reliable methods. Objective: The aim of the present study was to measure skin elasticity, capacitance, sebum content, pH and temperature in CS before and after 12 months of treatment. Methods: Twenty patients with CS and 11 healthy control subjects were included in the study. Skin properties were measured on dorsum of both hands by Cutameter, Corneometer CM825, Sebumeter SM810, Phmeter PH900 as non-invasive reliable measuring methods. Patients were treated for CS with surgery and they were reevaluated 12 months after. Results: The sebum content, temperature and capacitance of the skin were found to be significantly decreased in patients with CS compared to healthy controls on dorsum of both hands at baseline. The skin capacitance in CS was found to be similar to healthy controls after treatment, however the increment was not found to be significant compared to baseline. The sebum and temperature of the skin did not show significant changes according to baseline and was still significantly lower than healthy controls. Although statistically not significant, the elasticity of the skin was lower in CS than in the controls. The elasticity of the skin was found to be significantly increased a year after treatment. There was no correlation of skin elasticity, capacitance, temperature and sebum content of the skin with morning or midnight cortisol, urinary free cortisol or ACTH levels at baseline. Conclusion: This study revealed a hypothermic skin surface with decreased sebum secretion and capacitance and mildly decreased skin elasticity in CS. The decreased elasticity and capacitance of the skin may increase after treatment of CS.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Evaluation of pituitary functions in patients with traumatic maxillofacial fractures: preliminary results
Introduction: Traumatic brain injury (TBI) is a worldwide public health problem and has been recently documented as a cause of neuroendocrine dysfunction. It has been shown that hypopituitarism may develop nearly 10–20% of the TBI patients, and most common pituitary hormone deficiency after TBI is growth hormone deficiency (GHD). To date no study has evaluated the relation between isolated maxillofacial fractures and pituitary dysfunction. Therefore we aimed to investigate pituitary function in patients with traumatic maxillofacial fracture. Methods and results: Thirty patients who had traumatic maxillofacial fracture at least 12 months ago (mean 33.6 months) were included in the study retrospectively. Twenty-six of 30 patients (86.7) were male and 4 patients (13.3%) were female, and mean age of the study group was 39.8 years (range; 18–63). None of the patients had loss of consciousness after head trauma and they did not hospitalized in intensive care unit. The type of maxillofacial fractures were as follows: One patient had blow out, seven patients had Lefort 1–2, six patients had mandibula, three patients had nasal and thirteen patients had zygoma fractures. Basal hormone levels, Glucagon and 1 mcg ACTH stimulation tests were performed to investigate the pituitary functions. Four of 30 patients (13.3%) had isolated GH deficiency based on glucagon stimulation test (GST). Mean peak GH level after GST in patients with hypopituitarism (0.43 ng/ml) was significantly lower than the patients without hypopituitarism (6.7 ng/ml). Other anterior pituitary hormones were normal in all patients, and none of them had diabetes insipidus. Conclusion: These preliminary results suggest that there is a substantial risk for hypopituitarism, GH deficiency in particular, during the chronic phase of traumatic maxillofacial fractures. However these findings need confirmation with further prospective studies with higher number of patients.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Evaluation of pituitary functions in patients with traumatic maxillofacial fractures: preliminary results
Introduction: Traumatic brain injury (TBI) is a worldwide public health problem and has been recently documented as a cause of neuroendocrine dysfunction. It has been shown that hypopituitarism may develop nearly 10–20% of the TBI patients, and most common pituitary hormone deficiency after TBI is growth hormone deficiency (GHD). To date no study has evaluated the relation between isolated maxillofacial fractures and pituitary dysfunction. Therefore we aimed to investigate pituitary function in patients with traumatic maxillofacial fracture. Methods and results: Thirty patients who had traumatic maxillofacial fracture at least 12 months ago (mean 33.6 months) were included in the study retrospectively. Twenty-six of 30 patients (86.7) were male and 4 patients (13.3%) were female, and mean age of the study group was 39.8 years (range; 18–63). None of the patients had loss of consciousness after head trauma and they did not hospitalized in intensive care unit. The type of maxillofacial fractures were as follows: One patient had blow out, seven patients had Lefort 1–2, six patients had mandibula, three patients had nasal and thirteen patients had zygoma fractures. Basal hormone levels, Glucagon and 1 mcg ACTH stimulation tests were performed to investigate the pituitary functions. Four of 30 patients (13.3%) had isolated GH deficiency based on glucagon stimulation test (GST). Mean peak GH level after GST in patients with hypopituitarism (0.43 ng/ml) was significantly lower than the patients without hypopituitarism (6.7 ng/ml). Other anterior pituitary hormones were normal in all patients, and none of them had diabetes insipidus. Conclusion: These preliminary results suggest that there is a substantial risk for hypopituitarism, GH deficiency in particular, during the chronic phase of traumatic maxillofacial fractures. However these findings need confirmation with further prospective studies with higher number of patients.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Cardiovascular effects of obstructive sleep apnea syndrome (OSAS) on acromegaly
Introduction: Acromegaly is known to be associated with obstructive sleep apnea syndrome (OSAS) in about 60–70% of the cases. Both OSAS and acromegaly are thought to be responsible from cardiovascular diseases and endothelial dysfunction. The aim of the present study was to investigate the role of OSAS on cardiovascular effects of acromegaly. Materials and Methods: 25 patients with acromegaly and 7 healthy volunteers were enrolled into the study. Cardiac and endothelial functions were evaluated with echocardiography (ECHO), carotis intima-media thickness (CIMT), aortic stiffness and flow mediated dilatation (FMD). All subjects were performed polysomnography (PSG). Patients were categorized into 3 groups according to their apnea-hypopnea index (AHİ). AHİ of 15 as OSAS and between 5-15 as borderline. Results: 10 (40%) patients were found to have OSAS, 7 (28%) had borderline AHİ and 8 (32%) patients were normal. No differences were found between acromegaly and healthy controls in means of CIMT, aortic stiffness and ECHO parameters. FMD was found to be lower in acromegalic patients (8.9±4.7%) than in healthy controls (18.8±2.2%). FMD, CIMT, aortic stiffness and ECHO parameters were found to be similar in 3 acromegalic groups. No correlation was found between AHI and FMD, CIMT or aortic stiffness. Conclusion: Acromegaly leads to endothelial dysfunction. Presence of OSAS in acromegalic patients does not seem to cause further deterioration of cardiovascular or endothelial functions.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Cardiovascular effects of obstructive sleep apnea syndrome (OSAS) on acromegaly
Introduction: Acromegaly is known to be associated with obstructive sleep apnea syndrome (OSAS) in about 60–70% of the cases. Both OSAS and acromegaly are thought to be responsible from cardiovascular diseases and endothelial dysfunction. The aim of the present study was to investigate the role of OSAS on cardiovascular effects of acromegaly. Materials and Methods: 25 patients with acromegaly and 7 healthy volunteers were enrolled into the study. Cardiac and endothelial functions were evaluated with echocardiography (ECHO), carotis intima-media thickness (CIMT), aortic stiffness and flow mediated dilatation (FMD). All subjects were performed polysomnography (PSG). Patients were categorized into 3 groups according to their apnea-hypopnea index (AHİ). AHİ of 15 as OSAS and between 5-15 as borderline. Results: 10 (40%) patients were found to have OSAS, 7 (28%) had borderline AHİ and 8 (32%) patients were normal. No differences were found between acromegaly and healthy controls in means of CIMT, aortic stiffness and ECHO parameters. FMD was found to be lower in acromegalic patients (8.9±4.7%) than in healthy controls (18.8±2.2%). FMD, CIMT, aortic stiffness and ECHO parameters were found to be similar in 3 acromegalic groups. No correlation was found between AHI and FMD, CIMT or aortic stiffness. Conclusion: Acromegaly leads to endothelial dysfunction. Presence of OSAS in acromegalic patients does not seem to cause further deterioration of cardiovascular or endothelial functions.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
GH replacement therapy during pregnancy in a patient with Sheehan's syndrome
Introduction: Appropriate replacement therapy of not only gonadotrophins, but other deficient pituitary hormones is important in patients with hypopituitarism for a successful pregnancy. Data regarding GH replacement therapy during pregnancy is limited. We would like to present a case with panhypopituitarism including severe GH deficiency due to Sheehan’s syndrome, who achieved successful pregnancy with GH replacement therapy in the first half of pregnancy. Case: The patient was a 30-year-old woman with Sheehan’s syndrome diagnosed 3 years after her last delivery. She had panhypopituitarism and was treated with prednisolone, levothyroxine, combined estrogen–progesterone pills and GH. Since the patient wanted to concieve again, ovulation induction was carried out. Conception occurrred after second trial of ovulation induction. Prednisolone and levothyroxine doses were adjusted according to the trimester of her pregnancy and GH replacement therapy was continued until 20 weeks of gestation and the dose was adjusted according to her IGF1 levels. Normal IGF1 levels were maintained without exogenous GH until birth most likely due to placental GH secretion. The pregnancy and delivery were uneventful and the patient gave birth to a term healthy baby. Conclusion: The dose of deficient hormones should be adjusted according to trimester of pregnancy in patients with hypopituitarism. GH may be used in selected cases with hypopituitarism to increase the success of fertilization and implantation. GH needs to be discontinued in the second half of pregnancy since placental GH is able maintain normal IGF1 levels.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
GH replacement therapy during pregnancy in a patient with Sheehan's syndrome
Introduction: Appropriate replacement therapy of not only gonadotrophins, but other deficient pituitary hormones is important in patients with hypopituitarism for a successful pregnancy. Data regarding GH replacement therapy during pregnancy is limited. We would like to present a case with panhypopituitarism including severe GH deficiency due to Sheehan’s syndrome, who achieved successful pregnancy with GH replacement therapy in the first half of pregnancy. Case: The patient was a 30-year-old woman with Sheehan’s syndrome diagnosed 3 years after her last delivery. She had panhypopituitarism and was treated with prednisolone, levothyroxine, combined estrogen–progesterone pills and GH. Since the patient wanted to concieve again, ovulation induction was carried out. Conception occurrred after second trial of ovulation induction. Prednisolone and levothyroxine doses were adjusted according to the trimester of her pregnancy and GH replacement therapy was continued until 20 weeks of gestation and the dose was adjusted according to her IGF1 levels. Normal IGF1 levels were maintained without exogenous GH until birth most likely due to placental GH secretion. The pregnancy and delivery were uneventful and the patient gave birth to a term healthy baby. Conclusion: The dose of deficient hormones should be adjusted according to trimester of pregnancy in patients with hypopituitarism. GH may be used in selected cases with hypopituitarism to increase the success of fertilization and implantation. GH needs to be discontinued in the second half of pregnancy since placental GH is able maintain normal IGF1 levels.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Evaluation of long-term pituitary functions after hypoxia due to ventricular arrhythmias: a preliminary report
Introduction: Traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), stroke and cerebrovascular disease (CVD) are identified as risk factors for hypopituitarism. However, the mechanisms and the risk factors for the hypothalamo-pituitary dysfunction due to TBI, SAH, stroke and CVD are still unclear (1,2,3). Hypoxia, hypoxemia, neuroinflammation, autoimmunity could have impact in the pathogenesis (4). In patients with serious ventricular arrhythmias who need resuscitation, brain tissue may be exposed to short-term severe ischemia and hypoxia. However there are no data in the literature regarding pituitary dysfunction after ventricular arrhythmias. Materials and methods: Thirty patients with ventricular arrhythmias (25 male, five female) were included in the study. Basal hormone levels were measured. To assess GH – insulin like growth factor (IGF-1) axis glucagon stimulation test was performed and 1 μg ACTH stimulation test was used for assessing hypothalamic–pituitary–adrenal axis. Results: Four patients had secondary hypogonadism (13.3%). When the two stimulation tests and basal hormone levels were evaluated together no patient had ACTH deficiency, but glucagon stimulation test revealed GH deficiency in 8 of 30 (26.6%) patients. There were no statistical difference according to age, BMI, IGF-1 levels and other hormone levels between GH deficiency and GH sufficient group. However, IGF-1 levels were significantly lower in GH deficiency group. Discussion: In conclusion, present data clearly suggest that in patients with serious ventricular arrhythmias who need cardiac resuscitation, pituitary dysfunction is not uncommon. Future studies need to be done to understand whether routine screening of pituitary functions in this patient group is clinically relevant or not.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Evaluation of long-term pituitary functions after hypoxia due to ventricular arrhythmias: a preliminary report
Introduction: Traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), stroke and cerebrovascular disease (CVD) are identified as risk factors for hypopituitarism. However, the mechanisms and the risk factors for the hypothalamo-pituitary dysfunction due to TBI, SAH, stroke and CVD are still unclear (1,2,3). Hypoxia, hypoxemia, neuroinflammation, autoimmunity could have impact in the pathogenesis (4). In patients with serious ventricular arrhythmias who need resuscitation, brain tissue may be exposed to short-term severe ischemia and hypoxia. However there are no data in the literature regarding pituitary dysfunction after ventricular arrhythmias. Materials and methods: Thirty patients with ventricular arrhythmias (25 male, five female) were included in the study. Basal hormone levels were measured. To assess GH – insulin like growth factor (IGF-1) axis glucagon stimulation test was performed and 1 μg ACTH stimulation test was used for assessing hypothalamic–pituitary–adrenal axis. Results: Four patients had secondary hypogonadism (13.3%). When the two stimulation tests and basal hormone levels were evaluated together no patient had ACTH deficiency, but glucagon stimulation test revealed GH deficiency in 8 of 30 (26.6%) patients. There were no statistical difference according to age, BMI, IGF-1 levels and other hormone levels between GH deficiency and GH sufficient group. However, IGF-1 levels were significantly lower in GH deficiency group. Discussion: In conclusion, present data clearly suggest that in patients with serious ventricular arrhythmias who need cardiac resuscitation, pituitary dysfunction is not uncommon. Future studies need to be done to understand whether routine screening of pituitary functions in this patient group is clinically relevant or not.
- 1 February 2009
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 34 (2) , 212-219
Sleep architecture in Sheehan’s syndrome before and 6 months after growth hormone replacement therapy
- 1 February 2009
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 34 (2) , 212-219
Sleep architecture in Sheehan’s syndrome before and 6 months after growth hormone replacement therapy
- 28 February 2007
- Vol. 6 (1) , 71-4
Pubertal arrest due to Zn deficiency: the effect of zinc supplementation.
The Prasad Syndrome is characterized by iron deficiency anemia, hepatosplenomegaly, skin changes, hypogonadism, dwarfism and geophagia. Hypogonadism is a major manifestation of zinc (Zn) deficiency in both humans and animals. T he mechanism of hypogonadism caused by Zn deficiency has not been clarified. We present a 19 year-old boy with short stature, pubertal arrest, iron deficiency anemia and Zn deficiency. Based on the dynamic tests, the hypogonadism seems to be due to hypothalamic dysfunction. T he growth retardation was associated with low IGF-I and normal growth hormone (GH) secretion, indicating GH receptor or post receptor defect. Growth acceleration and testicular development was observed after Zn supplementation. Zn deficiency, although very rare, should be considered in patients with poor growth and hypogonadism associated with skin changes and anemia.
- 28 February 2007
- Vol. 6 (1) , 71-4
Pubertal arrest due to Zn deficiency: the effect of zinc supplementation.
The Prasad Syndrome is characterized by iron deficiency anemia, hepatosplenomegaly, skin changes, hypogonadism, dwarfism and geophagia. Hypogonadism is a major manifestation of zinc (Zn) deficiency in both humans and animals. T he mechanism of hypogonadism caused by Zn deficiency has not been clarified. We present a 19 year-old boy with short stature, pubertal arrest, iron deficiency anemia and Zn deficiency. Based on the dynamic tests, the hypogonadism seems to be due to hypothalamic dysfunction. T he growth retardation was associated with low IGF-I and normal growth hormone (GH) secretion, indicating GH receptor or post receptor defect. Growth acceleration and testicular development was observed after Zn supplementation. Zn deficiency, although very rare, should be considered in patients with poor growth and hypogonadism associated with skin changes and anemia.